ADAPTIMMUNE THERAPEUTICS PLC Deferred Revenue Recognized
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) reported Deferred Revenue Recognized of $5.81 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-08-13
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $5.68M, a 87.86% decline year-over-year.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $46.78M.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for the quarter ending 2020-09-30 was $400.00K.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for the quarter ending 2020-06-30 was $400.00K.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for fiscal 2023 was $59.07M, a 234.72% increase from fiscal 2022.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for fiscal 2022 was $17.65M.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for fiscal 2020 was $1.50M.
- ADAPTIMMUNE THERAPEUTICS PLC contract with customer, liability, revenue recognized for fiscal 2018 was $3.09M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $5.81M 10-Q · filed 2025-08-13 | ||||
| 2024-12-31 | $3.22M 10-Q · filed 2025-05-13 | $163.35M 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $161.01M 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $133.01M 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | $5.68M 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $59.07M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | $59.38M 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | $52.05M 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $46.78M 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | $17.65M 10-K · filed 2024-03-06 | ||||
| 2022-09-30 | $13.04M 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $7.34M 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | $1.50M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | $400.00K 10-Q · filed 2020-11-05 | $1.50M 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $400.00K 10-Q · filed 2020-08-06 | $1.20M 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $761.00K 10-Q · filed 2020-05-14 | ||||
| 2019-09-30 | $3.20M 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $3.20M 10-Q · filed 2019-08-01 | ||||
| 2018-12-31 | $3.09M 10-K · filed 2019-02-27 | ||||
| 2018-09-30 | $1.79M 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $11.91M 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $7.87M 10-Q · filed 2018-05-09 |